Publications by authors named "Seth B Forman"

Claim this Profile
L
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo.
David Rosmarin, Amit G Pandya, Thierry Passeron, Seth B Forman, Jacek Zdybski

Dermatol Ther (Heidelb)· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Open-label treatment extension of ruxolitinib cream in vitiligo: findings from the TRuE-V long-term extension phase 3 study.
John E Harris, Kim Papp, Khaled Ezzedine, Michael Sebastian, Amit G Pandya, Seth B Forman

Br J Dermatol· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy of Roflumilast Foam 0.3% in Patients with Seborrheic Dermatitis: A Phase II, Open-Label Trial of up to 52 Weeks.
Andrew F Alexis, Michael Bukhalo, Fran E Cook-Bolden, James Q Del Rosso, Zoe D Draelos, Seth B Forman

Am J Clin Dermatol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with atopic dermatitis: Results from TRuE-AD3, a phase 3, randomized double-blind study.
Lawrence F Eichenfield, Linda F Stein Gold, Eric L Simpson, Andrea L Zaenglein, April W Armstrong, Seth B Forman

J Am Acad Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term Safety and Efficacy with Roflumilast Cream 0.15% in Patients Aged ≥6 Years with Atopic Dermatitis: A Phase 3 Open-Label Extension Trial.
Eric L Simpson, Lawrence F Eichenfield, Kim A Papp, Seth B Forman, Adelaide A Hebert

Dermatitis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Eric L Simpson, Lawrence F Eichenfield, Javier Alonso-Llamazares, Zoe D Draelos, Laura K Ferris, Seth B Forman

JAMA Dermatol· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Andrew Blauvelt, Zoe D Draelos, Linda Stein Gold, Javier Alonso-Llamazares, Neal Bhatia, Seth B Forman

J Am Acad Dermatol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Matthew J Zirwas, Zoe D Draelos, Janet DuBois, Leon H Kircik, Angela Y Moore, Seth B Forman

JAMA Dermatol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: Results from two phase 3 studies.
Kim Papp, Jacek C Szepietowski, Leon Kircik, Darryl Toth, Lawrence F Eichenfield, Seth B Forman

J Am Acad Dermatol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe disease.
Jonathan T Sims, Ching-Yun Chang, Richard E Higgs, Sarah M Engle, Yushi Liu, Seth B Forman

Exp Dermatol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Kim Papp, Jacek C Szepietowski, Leon Kircik, Darryl Toth, Lawrence F Eichenfield, Seth B Forman

J Am Acad Dermatol· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-Blind, Placebo-Controlled Trial.
Seth B Forman, David M Pariser, Yves Poulin, Michael S Vincent, Steven A Gilbert

J Invest Dermatol· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.
Melinda J Gooderham, Seth B Forman, Robert Bissonnette, Jean S Beebe, Weidong Zhang

JAMA Dermatol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study.
Emma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, Seth B Forman, August Wilke

J Am Acad Dermatol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
Alexa B Kimball, Martin M Okun, David A Williams, Alice B Gottlieb, Kim A Papp, Seth B Forman

N Engl J Med· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Check your skin: insights regarding skin cancer education.
William Gillen, Seth B Forman, Julia R Nunley, Sonya Bhole, Kyle Eliason

J Am Acad Dermatol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantification of melanocytes in sun-damaged skin.
Katherine Madden, Seth B Forman, Dirk Elston

J Am Acad Dermatol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Success of oxandrelone in the treatment of decubitus ulcers.
Katherine B Madden, Agyrios Stampas, Seth B Forman

J Drugs Dermatol· June 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The significance of melanoma subsets.
Lester F Libow, Seth B Forman, Tammie C Ferringer, Maj Steven J Peckham, Maj Scott R Dalton

J Am Acad Dermatol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Psoriasis and psoriatic arthritis in a patient with HIV: response to mycophenolate mofetil treatment.
Seth B Forman, Robert Higginson, Algin B Garrett

J Drugs Dermatol· October 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is superficial spreading melanoma still the most common form of malignant melanoma?
Seth B Forman, Tammie C Ferringer, Steven J Peckham, Scott R Dalton, Geoff T Sasaki

J Am Acad Dermatol· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Penile granuloma annulare of an adolescent male--case report and review of the literature.
Seth B Forman, Joel M Sumfest, Howard B Pride, Tammie C Ferringer

Pediatr Dermatol· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collision tumor composed of Merkel cell carcinoma and lentigo maligna melanoma.
Seth B Forman, Dennis A Vidmar, Tammie C Ferringer

J Cutan Pathol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
S100 A6 immunohistochemical staining for spindle cell and desmoplastic melanomas.
Puja Kumari Puri, Seth B Forman, Tammie Ferringer, Dirk Elston

J Cutan Pathol· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Glomeruloid hemangiomas without POEMS syndrome: series of three cases.
Seth B Forman, William B Tyler, Tammie C Ferringer, Dirk M Elston

J Cutan Pathol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis